FIELD: biotechnology.
SUBSTANCE: antibody that binds to tumor tissue, where the antibody binds to an extracellular RNA-protein complex, as well as to a method for its production. Also a vector and a cell containing polynucleotides encoding the VH and VL regions of this antibody are proposed.
EFFECT: efficient for inducing an immune response and for inhibiting the growth of tumor cells.
31 cl, 64 dwg, 3 tbl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO TAU AND THEIR USE | 2018 |
|
RU2787779C2 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
| ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
| CHIMERIC ANTIGEN RECEPTORS AND BINDING AGENTS TARGETING DLL3 | 2020 |
|
RU2822366C2 |
| SOLUBILIZED APIRASES, METHODS AND APPLICATIONS | 2019 |
|
RU2791992C2 |
| STABLE COMPOSITIONS OF ANTI-TIGIT ANTIBODIES, INDIVIDUALLY AND IN COMBINATION WITH ANTIBODIES AGAINST PROGRAMMED DEATH RECEPTOR 1 (PD-1), AND METHODS OF THEIR USE | 2018 |
|
RU2820576C2 |
| ANTIGEN-BINDING PROTEINS AGAINST TIGIT AND THEIR APPLICATION METHODS | 2018 |
|
RU2776714C2 |
| CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
| BISPECIFIC PROTEIN | 2019 |
|
RU2784486C1 |
| ANTIBODIES TO ENTPD2, TYPES OF COMBINATION THERAPY AND METHODS FOR USING ANTIBODIES AND TYPES OF COMBINATION THERAPY | 2019 |
|
RU2790991C2 |
